The goal of this retrospective observational study is to characterize multiple myeloma (MM) patients (by collecting demographics, disease characteristics and treatment history data) treated in first or second relapse with belantamab mafodotin combinations under compassionate use conditions.
The main question it aims to answer is which belantamab combinations (belantamab mafodotin+bortezomib+dexamethasone \[BVd\] vs. belantamab mafodotin+pomalidomide+dexamethasone \[BPd\]) show higher response rates in patients with MM in first or second relapse.